Literature DB >> 8335921

Role and effect of IL-2 in experimental visceral leishmaniasis.

H W Murray1, G D Miralles, M Y Stoeckle, D F McDermott.   

Abstract

In experimental visceral leishmaniasis, acquired resistance is T cell-dependent, involves IFN-gamma-activated macrophages, and is expressed in the tissues by granuloma formation. Resistance also correlates with Ag-stimulated IL-2 secretion; therefore, Leishmania donovani-infected BALB/c mice were treated with anti-IL-2 mAb or rIL-2 to determine the host defense effect of IL-2. In control mice, intracellular hepatic infection peaked at 2 wk and then declined coincident with granuloma development. In contrast, liver parasite burdens in anti-IL-2-treated mice continued to increase until after 4 wk, at which time mature granuloma formation was inhibited. Treatment of mice with continuously administered IL-2 reduced liver burdens by > 50% and led to marked accumulation of granuloma mononuclear cells. The IL-2-responsive mechanism was T cell-dependent and required both L3T4+ and Lyt-2+ cells. IL-2 enhanced IFN-gamma mRNA expression in vivo and was required for IFN-gamma secretion in vitro, and anti-IFN-gamma mAb administration abolished the antimicrobial effect of exogenous IL-2. These results: 1) identify the activity of endogenous IL-2 in both antileishmanial resistance and granuloma formation; 2) demonstrate that exogenous IL-2 can enhance the granulomatous tissue reaction; and 3) indicate that IL-2 treatment stimulates intracellular antimicrobial activity largely via the induction of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335921

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

3.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Immunomodulatory peptide from cystatin, a natural cysteine protease inhibitor, against leishmaniasis as a model macrophage disease.

Authors:  Snigdha Mukherjee; Anindita Ukil; Pijush K Das
Journal:  Antimicrob Agents Chemother       Date:  2007-03-05       Impact factor: 5.191

5.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Authors:  Yasuyuki Goto; Lisa Y Bogatzki; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2007-08-20       Impact factor: 3.641

6.  Regulation of impaired protein kinase C signaling by chemokines in murine macrophages during visceral leishmaniasis.

Authors:  Ranadhir Dey; Arup Sarkar; Nivedita Majumder; Suchandra Bhattacharyya Majumdar; Kaushik Roychoudhury; Sandip Bhattacharyya; Syamal Roy; Subrata Majumdar
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.

Authors:  Jayati Mookerjee Basu; Ananda Mookerjee; Prosenjit Sen; Suniti Bhaumik; Pradip Sen; Subha Banerjee; Ksudiram Naskar; Soumitra K Choudhuri; Bhaskar Saha; Sanghamitra Raha; Syamal Roy
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

8.  Leishmania donovani inhibits macrophage apoptosis and pro-inflammatory response through AKT-mediated regulation of β-catenin and FOXO-1.

Authors:  Purnima Gupta; Supriya Srivastav; Shriya Saha; Pijush K Das; Anindita Ukil
Journal:  Cell Death Differ       Date:  2016-09-23       Impact factor: 15.828

9.  Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease.

Authors:  S Dubucquoi; A Janin; O Klein; P Desreumaux; P Quandalle; A Cortot; M Capron; J F Colombel
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

10.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.